Published online Aug 27, 2013. doi: 10.4254/wjh.v5.i8.439
Revised: June 10, 2013
Accepted: July 18, 2013
Published online: August 27, 2013
Processing time: 159 Days and 17.3 Hours
AIM: To evaluate the efficacy of the aspartate aminotransferase/platelet ratio index (APRI) and neutrophil-lymphocyte (N/L) ratio to predict liver damage in chronic hepatitis B (CHB).
METHODS: We analyzed 89 patients diagnosed with CHB by percutaneous liver biopsy and 43 healthy subjects. Liver biopsy materials were stained with hematoxylin-eosin and Masson’s trichrome. Patients’ fibrosis scores and histological activity index (HAI) were calculated according to the Ishak scoring system. Fibrosis score was recognized as follows: F0-1 No /early-stage fibrosis, F2-6 significant fibrosis, F0-4 non-cirrhotic and F5-6 cirrhotic. Significant liver fibrosis was defined as an Ishak score of ≥ 2. APRI and N/L ratio calculation was made by blood test results.
RESULTS: The hepatitis B and control group showed no difference in N/L ratios while there was a significant difference in terms of APRI scores (P < 0.001). Multiple logistic regression analysis revealed that the only independent predictive factor for liver fibrosis in CHB was platelet count. APRI score was significantly higher in cirrhotic patients than in non-cirrhotic patients. However, this significance was not confirmed by multiple logistic regression analysis. The optimum APRI score cut-off point to identify patients with cirrhosis was 1.01 with sensitivity, specificity, positive predictive value and negative predictive value of 62% (36%-86%), 74% (62%-83%), 29% (13%-49%) and 92% (82%-97%), respectively. In addition, correlation analyses revealed that N/L ratio has a negative and significant relationship with HAI (r = -0.218, P = 0.041).
CONCLUSION: N/L ratio was negatively correlated with HAI. APRI score may be useful to exclude cirrhosis in CHB patients.
Core tip: Due to the limitations of liver biopsy, the use of non-invasive markers has emerged in recent years. The aspartate aminotransferase/platelet ratio index (APRI) is used to determine chronic hepatitis C patients with advanced fibrosis. Neutrophil-lymphocyte (N/L) ratio is higher in patients with advanced fibrosis and considered as a novel non-invasive marker to predict advanced disease in non-alcoholic steatohepatitis. This study showed that N/L ratio is negatively correlated with HAI in chronic hepatitis B (CHB). APRI score may be useful to exclude cirrhosis in CHB patients.